Pharmexcel Ltd Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 06841897

Pharmexcel Ltd

Filleted Unaudited Financial Statements

31 March 2025

Pharmexcel Ltd

Statement of Financial Position

31 March 2025

	2025		2024
Note	£	£	£

Fixed assets

Tangible assets	5		17,966	20,143

Current assets

Debtors	6	561,781	556,756
Cash at bank and in hand		1,127,155	1,303,991
		------------	------------
		1,688,936	1,860,747

Creditors: amounts falling due within one year	7	731,923		526,213
		------------		------------
Net current assets			957,013	1,334,534
			---------	------------
Total assets less current liabilities			974,979	1,354,677

Provisions

Taxation including deferred tax	3,414	3,827
	---------	------------
Net assets	971,565	1,350,850
	---------	------------

Capital and reserves

Called up share capital	1,000	1,000
Profit and loss account	970,565	1,349,850
	---------	------------
Shareholders funds	971,565	1,350,850
	---------	------------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 31 March 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

Pharmexcel Ltd

Statement of Financial Position (continued)

31 March 2025

These financial statements were approved by the board of directors and authorised for issue on 26 November 2025 , and are signed on behalf of the board by:

Mrs Y M Enever
Director

Company registration number: 06841897

Pharmexcel Ltd

Notes to the Financial Statements

Year ended 31 March 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 40 Kimbolton Road, Bedford, MK40 2NR, Bedfordshire.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in sterling, which is the functional currency of the entity.

Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods supplied and services rendered, stated net of discounts and of Value Added Tax. Revenue from ongoing projects is recognised in the period in which it arises based on the judgement of the directors as to the relative completion of each project versus the amounts invoiced. Any amounts invoiced in advance of work being completed is deferred to the period in which the work is carried out.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. In this case, tax is recognised in other comprehensive income or directly in equity, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Foreign currencies

Foreign currency transactions are initially recorded in the functional currency, by applying the spot exchange rate as at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated at the exchange rate ruling at the reporting date, with any gains or losses being taken to the profit and loss account.

Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

	Equipment	-	25% reducing balance

Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost.

Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 17 (2024: 27 ).

5. Tangible assets

	Equipment	Total
	£	£
Cost
At 1 April 2024	41,222	41,222
Additions	4,050	4,050
Disposals	( 2,827)	( 2,827)
	--------	--------
At 31 March 2025	42,445	42,445
	--------	--------
Depreciation
At 1 April 2024	21,079	21,079
Charge for the year	5,451	5,451
Disposals	( 2,051)	( 2,051)
	--------	--------
At 31 March 2025	24,479	24,479
	--------	--------
Carrying amount
At 31 March 2025	17,966	17,966
	--------	--------
At 31 March 2024	20,143	20,143
	--------	--------

6. Debtors

	2025	2024
	£	£
Trade debtors	173,518	190,518
Other debtors	388,263	366,238
	---------	---------
	561,781	556,756
	---------	---------

7. Creditors: amounts falling due within one year

	2025	2024
	£	£
Trade creditors	109,332	85,906
Social security and other taxes	144,278	112,520
Other creditors	478,313	327,787
	---------	---------
	731,923	526,213
	---------	---------

8. Other financial commitments

Other financial commitments which are not included in the balance sheet amount to £8,139 (2024 - £15,233).